Skip to content

READZER / INDUSTRY INTELLIGENCE

Industry desk

Follow important changes. Read the original evidence.

Nov 22 · UTC

Your reading desk
Newest first

Summary preview

Back to updates

RAS-targeting small molecules redefine pancreatic cancer treatment

PLOS Medicine ·

What to know

A Perspective in PLOS Medicine highlights that treatment for pancreatic adenocarcinoma is moving beyond cytotoxic chemotherapy, with recent advances in RAS-targeting small molecule inhibitors reshaping therapeutic paradigms. The authors discuss clinical trial results and the ongoing challenge of treatment resistance.

Loading reading state…

Source and evidence

PLOS MedicineOriginal language · und ·

Original author: Samuel P. Soff, Eileen M. O’Reilly · PLOS Medicine Readzer provides an abridged translation. CC-BY-4.0.Source licence

Why it matters by industry
  • Healthcare & Life Sciences

    Directly relevant to oncology drug development and clinical practice, as it summarizes emerging RAS-targeted therapies for a difficult-to-treat cancer.

Reviewed summary. The complete article remains at its original source.